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ABSTRACT
Oral (OSCC) and cutaneous (CSCC) squamous cell carcinomas are epithelial neoplasms, 
which are both derived from keratinocyte cells. However, the etiology and prognosis of 
OSCC and CSCC are different. The main etiological factors behind OSCC are tobacco 
smoke and alcohol consumption, and for CSCC it is UV-radiation. OSCC has poorer 
prognosis than CSCC. 
In order to be invasive, cancer cells have to pass various barriers. They have to disrupt 
cell-to-cell junctions, penetrate basement membranes, and invade connective tissue. 
The pattern of invasion of tumors varies strikingly. Some invade in large border fronts 
while others invade in single cell manner. Expression of the transmembrane proteins, 
E-cadherin and syndecan-1, in cell membrane are lost during tumor invasion, and therefore 
loosening cell adhesion. Matrix metalloproteinases (MMP) are tissue proteinases, which 
have a proteolytic role in various physiological events and during tumor progression 
MMPs are capable of degrading extracellular matrix (ECM) proteins but also have an 
immunomodulatory role. Toll-like receptors (TLRs) are part of the innate immunity and 
can recognize exogenous pathogen associated molecular patterns or endogenous damage 
associated molecular patterns. Cancer cells may use TLRs to induce tumor-promoting 
????????????
The aim of the study was to examine possible cellular and molecular differences between 
OSCC and CSCC explaining their different behaviors as cancers despite having cellular 
similarities. The study included 36 OSCC and 27 CSCCs from patients with early stage 
???????????????????? ???????????????????? ????????????? ???????????????? ??????????????? ??
histological risk assessment (HRA) model and histological risk assessment score (HRS). 
We performed immunohistochemical staining for E-cadherin, Snail (Snail1), Syndecans 
??????????? ????????????????????????????????????????????????????????????????????????????
?????? ???????????????????? ???????????????????????????????????????????????? ?????????????
studied.
?????????????????? ??????????????????????????????????? ?????????????????????????????????
with the invasion depths of the OSCC tumors. OSCC had a more severe histological 
pattern of invasion than CSCC. E-cadherin and Syndecan-1 expression decreased in the 
invasive front of OSCCs and CSCCs. Syndecan-1 expression in the tumor stroma was 
???????????????????????????????????????????????????????????????????????????????
7 was mainly expressed in the invasive front of OSCC and CSCC and was stronger in 
OSCC than in CSCC. MMP-8 and MMP-9 were mainly expressed in the peritumoral 
???????????? ????????????? ??????????????? ????????? ???????? ????? ????????? ??? ???????
?????????????????????????????????????????????????????????????????????????????????????????
oral and cutaneous cell lines, but failed to do so with the most aggressive oral cancer cell 
line.  
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????????????????????????????????????????????????????????????????????????????????????????
CSCC patients. Increased stromal syndecan-1 expression in OSCC, MMP-7 expression 
???????????????????????????????????????? ???????????????????????????????????????????
partly explain the differences in survival between OSCC and CSCC.
15
INTRODUCTION
Normal oral mucosa and cutaneous tissue have mainly similar functions and structure. 
????????? ??????????????????????????????????????????????????????????????????????????????
?????????????????????????????? ????????????????????????????????????????????????????? ?????
mitosis takes place, a prickle layer, a granular layer, and a keratinized layer.  The epithelium 
functions as a barrier against external threats such as pathogens, chemicals and other 
substances. It also has various other physiological functions. Epithelial cells are called 
keratinocytes. Tight junctions attach these cells to each other. Connective tissue gives the 
epithelium strength and nourishes it. Oral mucosa has varying degree of keratinization. 
Cutaneous tissue is mainly keratinized.  Normal cutaneous appendages such as sweat 
glands and hairs are mainly absent in oral mucosa.(1,2)
Normal keratinocytes evolve through premalignant lesions to full-blown invasive cancer 
in a multistep process, in which multiple mutations modulate cells until these cells become 
cancer cells. Although different cells can achieve this cancerous stage by various means, 
Hanahan and Weinberg suggested in 2000 six acquired capabilities ‘hallmarks of cancer’ 
????????????????????????????????????????????????????????????????????????????????????????????
from external growth signals, having an insensitivity to growth-inhibitory signals, 
evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, 
and activating tissue invasion and metastasis. In recent studies numerous new ‘cancer 
hallmarks’ have been suggested and the events underlying these have been studied. This 
concept is timely and very evident in carcinomas.?????
16
REVIEW OF THE LITERATURE
ORAL SQUAMOUS CELL CARCINOMA
Oral squamous cell carcinoma (OSCC) is an epithelial neoplasia and the most common 
oral cancer. It can appear in all oral anatomical sites. Non-tongue oral cancers are located 
??????????????????????????????? ??????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
??????????? ?????????????????????????????????????????????????? ????????????? ??????????????
tongue (ICD C02) and basal tongue (ICD C01).(5,6)??????????????????????????????????????
cancer in the literature (7)???????????????????????????????? ??????????????????????????????????
??? ???? ????????????????? ?????????????? ?????? ??????????????????????????????????? ????????
?????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
pharynx, lip and oral cavity, paranasal sinus and nasal cavity, salivary gland and occult 
primaries of the head and neck (8).    
Etiology
The major etiological factors for OSCC are tobacco smoke and alcohol.  Other risk factors 
are chewing tobacco, human papilloma virus (HPV), betel chewing, and poor oral health.
(9) The increased risk of oral cancer among smokers has been evident for  almost half-
??????????????????????????????????????????????????? ????????????????????????? ?????????????
when compared to non-smokers and the risk increases with the frequency and duration of 
smoking in one’s lifetime.(10,11) After cessation of smoking, the risk of oral cancer, due to 
?????????????????????????????????????????????????????(12). Chewing tobacco is considered 
to have an increased risk (users odd ratio (OR) = 9.5, non-users OR = 3.6) and mortality 
for oral cancer ??????????????????????????????????????????????????????????????????? ???????
frequency of check-ups, and periodontal disease are associated with increased risk of 
oral cancer even when potentially confounding factors have been taken into account (9). 
Although Scandinavian smokeless tobacco (tobacco placed under the lip, sinus) has not 
been reported to increase the risk of oral cancer, it has been reported to cause mucosal 
lesions (15-18). 
In various analyses the risk of oral cancer due to alcohol increases accordingly with 
the daily quantity, duration of drinking, and with the lifetime cumulative consumption. 
Overall, the risk of oral cancer due to alcohol consumption is about 18% (19). The combined 
use of tobacco and alcohol multiplies their independent risks of developing oral cancer 
??????????????????????(9) 
Betel quid is a chewable stimulant containing an areca nut, betel leaves and sometimes 
tobacco (20). Betel chewing has a higher risk for oral cancer than smoking or alcohol 
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consumption ORs for chewing betel being 1.5-3 times and 2-11 times higher than ORs for 
smoking or alcohol consumption, respectively (21). 
Incidence and mortality
In Nordic countries (Sweden, Iceland, Norway, Finland, and Denmark) age standardized 
incidence rates (ASR) of oral cancer have been increasing in both men and females. The 
increase has been higher with men from 1.05 (per 100,000 persons) in 1971 to 1.8 (per 
100,000 persons) in 2011 and in women from 0.6 to 1.1 (per 100,000 persons). Time 
trend analysis reveals that incidence rates among males and females have stayed relatively 
??????????????????????????????????????????????????????????????????????????????????????
70+ years) incidence rates have been increasing until the late 2000s. Since 2007 incidence 
rates have decreased among 50-69 and 70+ years old females (Figure 1,2).  In men 
mortality of oral cancer has increased from 0.5 in 1971 to the highest peak 0.8 in 1991-92 
and descended to 0.6 in 2011. With women mortality of oral cancer in 1971 stood at 0.37 
in 1996 and descended to 0.32 in 2011 (Figure 3).(22)  
Figure 1. Age standardized incidence rates of mouth cancer in Nordic countries (22). 
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Figure 2a. Incidence rates (age cohorts) of mouth cancer in Nordic countries (male) (22).
Figure 2b. Incidence rates (age cohorts) of mouth cancer in Nordic countries (female) 
(22).
19
????????????????????????????????????
????? ????????? ????? ??????????? ???? ?????????? ??? ?????????????????? ??????? ????
histopathologically graded into well-, moderately-, and poorly differentiated (Table 1). 
OSCC cells, depending on differentiation, have varying degrees of abnormal mitotic 
activations, mitoses, and nuclear pleomorphisms. Well-differentiated carcinoma cells 
resemble normal squamous epithelium with keratin pearl formation. Moderately 
differentiated carcinoma cells are still recognized to be of epithelial origin, but have 
less keratin pearl formation. Poorly differentiated OSCC loses its epithelial looks and 
keratin pearl formation is absent.  In the invasive front, OSCC tumor cells invade in 
???? ???????????????????????????????????????????????????????? ????????? ?????? ????? ?????????
OSCC metastasizes mainly via lymphatic vessels, but vascular and perineural-invasions 
are common. (5) 
Treatment and prognosis
Stage of the cancer dictates the treatment of the OSCC. Early (stage I-II) cancers 
????????????????????????? ???? ????????????? ?????????? ?????????????? ????????? ????????
adjuvant radio or chemoradiotherapy is used.???? Treatment of neck in oral cancer 
depends on stage of the cancer and on lymph node status: neck dissection can be 
??????????? ??? ?????????? ???? ???????? ??? ???????? ????? ??????????? (25). According to 
????????? ???????? ????????????? ?????????????????? ????????????????????????????????? ??? ????
??????????????????????????????????????????????????????????????????????????????? (22). 
Figure 3. Age standardized mortality rates of mouth cancer in Nordic countries (22).
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Table 1.????????????????????????????????????????????????????????????????????????-
sion from Wiley Global (23)).
Table 2. Five-year age standardized relative survival (%) of OSCC patients diagnosed 
between the years 2009 and 2013 in Nordic countries(22). 
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CUTANEOUS SQUAMOUS CELL CARCINOMA
Cutaneous squamous cell carcinoma (CSCC) is an epithelial neoplasia and the second 
most common nonmelanoma skin cancer after basal cell carcinoma (26). In this thesis 
???????????? ????? ???????? ???? ??????? ??? ?????? ???? ????????????????????? ??????????
of the skin (basal and squamous cell carcinomas, malignant neoplasm of sebaceous and 
????????????????????????????????????????????????????????????????????
Etiology
The major factor behind the CSCC is UV-light and it is especially prominent in light-
skinned individuals. Almost 60 percent of CSCC are found in sun exposed head and neck 
regions (27). The incidence increases with cumulative sun exposure and aging (28,29). Immune 
suppression is considered as a high risk for developing CSCC. The incidence of CSCC 
among renal transplant patients is 18-36 times more frequent than in the general population 
(28). Smoking doubles the relative risk of CSCC and it is regarded as an independent risk 
factor for CSCC (30).  In addition chemical carcinogens, thermal injury, chronic radiation, 
and human papillomavirus are found to be etiological factors behind CSCC (31). 
Incidence and mortality
The ASR for the non-melanoma skin cancers has been steadily increasing over the past 30 
years in Nordic countries. In men the incidence rate has increased from 7 to 16 per 100,000 
persons and for women from 3 to 10 per 100,000 persons. With time trend analysis we can 
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
men and in women (Figure 6)(22). 
22
Figure 4. Age standardized incidence rates of nonmelanoma skin cancer in Nordic coun-
tries (22).
Figure 5a. Incidence rates (age cohorts) of non-melanoma skin cancer in Nordic coun-
tries (male) (22).
23
Figure 6. Age standardized mortality rates of non-melanoma skin cancer in Nordic 
countries (22). 
Figure 5b. Incidence rates (age cohorts) of non-melanoma skin cancer in Nordic coun-
tries (female) (22).
24
????????????????????????????????????
?????????? ????????? ????? ??????????? ???? ?????????? ??? ???????? ????????? ??? ???? ????
????????????????????????????????????????????????????????????????????????????????????????
a different degree of keratinization. Well-differentiated CSCC has a greater amount of 
keratinization and a more normal cytological appearance. Moderately differentiated CSCC 
manifest a lesser degree of keratinization and more mitotic activity.  Poorly differentiated 
CSCC has almost no keratinization and the cells resemble mesenchymal cells having lost 
their epithelial origin. CSCC metastasizes mostly via lymphatic vessels, but vascular and 
perineural-invasions are common (32).
Table 3.?????????????????????????????????????????????????????????????????????????
from Wiley Global (23)).
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Treatment and prognosis
The majority of CSCC cases are treated with surgical methods, which are electrodissecation, 
cryosurgery, topical chemotherapy and surgical excision. Radiotherapy is used with more 
aggressive lesions. Metastatic CSCC lesions are treated with adjuvant radiotherapy (33). In 
?????????????????????????????????????????????????????????????????????????????????????????
????????????????? ???????????????????????????????????????????????????????????(22) . 
 BIOMARKERS IN CANCER 
??????????????????????????????????????????????????????????????????????????????????????
as a “characteristic that is objectively measured and evaluated as an indicator of normal 
biologic processes, pathogenic processes or pharmacologic response to a therapeutic 
intervention”. A biomarker can be any molecule secreted by tumor cells, the body’s 
????????????????????????????????????????? ??????????????????????? ?????????????????  
In clinical use only few new cancer biomarkers have emerged in the past 25 years. 
????????? ??????????????????????????????????????????? ??????? ??? ?????????????????????
inexpensive screening tool is time consuming, expensive, and laborious (35). In 2001 
Pepe et al published their proposal for “biomarker development for early detection of 
??????????????????????????????????????????????????????????????????????????????????????????
to identify possible biomarkers in tumor tissue. The second phase is the development of a 
noninvasive clinical assay that can distinguish cancerous from noncancerous specimens. 
The third phase is a retrospective longitudinal study to assess the biomarker’s ability to 
???????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
reduce cancer mortality.(36)    
In addition to screening, some biomarkers are developed as prognostic markers for early 
stage cancers. These biomarkers should be able to distinguish the subset of cancers that 
are more likely to develop metastasis or local recurrence.  
Table 4. Five-year age standardized relative survival (%) of OSCC patients diagnosed 
between 2009 and 2013 in the Nordic countries(22). 
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At the moment various biomarkers are used to estimate the risk of developing cancers. 
They are also used in screening, determining prognosis or in differential diagnosis. 
Breast and ovarian cancers due to the mutation of breast cancer 1 and 2, early onset genes 
(BRCA1 and BRCA2) are the most frequent hereditary breast and ovarian cancers, thus 
genetic tests are used in estimating the risk of developing these cancers in families with 
a history of BRCA1/2 gene mutations (37,38). Kirsten rat sarcoma viral oncogen homolog 
(KRAS) mutation in colorectal cancer is associated with poorer prognosis and thus is a 
prognostic marker (38).  In the treatment of breast cancer multiple biomarkers are used to 
characterize the disease and to individualize the treatment. Traditional clinicopathological 
characteristic (tumor size, nodal status, tumor grade, lymphatic and vascular invasion) 
dictate primary treatment and the adjuvant radio and/or chemotherapy in breast cancer. 
At the moment predictive and prognostic biomarkers such as tumor hormone receptor 
and human epidermal growth factor receptor 2 (HER2)/neu status, BRCA1/2 status are 
substantially affecting treatment plans (39).
EPITHELIAL-MESENCYMAL TRANSITION
Epithelial-mesenchymal and mesenchymal-epithelial transitions
Epithelial and mesenchymal cells differ. Epithelial cells form layers of tightly attached 
cells, which are closely connected via tight junctions, which are desmosomes, adherens 
junctions and gap junctions. Epithelial cells have apicobasal polarization and basement 
membrane under their epithelial layers. Mesenchymal cells do not usually form any 
layers, nor do they have any polarization. Mesenchymal cells are capable of moving in 
connective tissue ????. Epithelial cells can be converted to mesenchymal cells in a process 
called epithelial-mesenchymal transition (EMT). EMT is a multi-step process in which 
epithelial cells obtain mesenchymal properties and lose their epithelial characteristics. The 
reverse process is named mesenchymal-epithelial transition (MET). EMT and MET have 
important roles during embryonic development ????. EMT is needed in tissue regeneration, 
???????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????. 
E-cadherin and Snail
E-cadherin is a transmembrane glycoprotein found at adherens junctions ????. E-cadherin 
has a direct role in cell adhesion and in controlling cell polarity ????.  During tumor invasion 
cancer cells experience EMT-like transition. The crucial step of EMT and tumor progression 
is the loosing of the E-cadherin in the cell membrane ????. In addition, other epithelial 
markers (desmoplakin, cytokeratin-18, Muc-1) are downregulated and mesenchymal 
??????????????????????????????????????????????????????????. One of the main repressors 
??????????????????????????????????????????????????????????????????????????????????????????
factors.  Snail binds to E-cadherin promoter and represses the e-cadherin transcription. 
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This leads to loosening of the cell-to-cell adhesion and cell polarity ???????. EMT-signaling 
is very complex, but the majority of the EMT-inducers repress E-cadherin expression via 
the Snail family ????. Meta-analysis of head and neck squamous cell carcinoma (HNSCC) 
studies found that decreased or abnormal E-cadherin expression was associated with a 
poorer prognosis ????.  
Syndecans
Syndecans are a family of transmembrane proteins with heparin- and/or chondroitin 
????????????????????????????????????????????????????????????????????????????????????????
????. Syndecans interact with various ECM proteins and growth factors (50). Syndecans 
are cleaved proteolytically in a process known as shedding. The extracellular portion of 
the syndecan molecule can become a soluble agonist/antagonist and the shedding also 
downregulates traditional syndecan signal transductions (51).
Syndecan-1 is mainly expressed in epithelial tissue. Syndecan-1 regulates cell-to-cell and 
cell-to-ECM interactions. In the murine model, over-expression of syndecan-1 is reported 
to have an effect on delaying skin wound repair (50). In oral epithelial dysplasia and in 
OSCC decreased syndecan-1 expression is found. In addition, low syndecan-1 expression 
in an invasive front is associated with a poor prognosis  (52,53).
Syndecan-2 is mainly expressed in mesenchymal cells and in neural tissues.  Syndecan-2 
promotes angiogenesis via vascular endothelial growth factor (VEGF) signaling and in 
syndecan-2-/- murine model the suppression of intersegmental vessels has been reported 
(50). In lung carcinoma murine model syndecan-2 expression suppressed metastasis partly 
by inhibiting the activation of MMP-2 ????. In contrast, up-regulation of syndecan-2 has 
been reported in colon cancers (55).
TUMORS AND THEIR MICROENVIRONMENTS 
Epithelial and connective tissue cells communicate via different signaling methods e.g. 
by cell-to-cell interactions or via secreted molecules (56). Epithelium and connective tissue 
together form a microenvironment and this sustains tissue integrity and cellular function. 
In pathological tissue and especially in tumors, cancer dependent changes may modify the 
tumor-stroma-cell interaction and promote the invasion and progression of tumors (56,57). 
???????????
??????????? ???????????? ???? ????? ????????? ????? ??? ??????? ?????????? ?????????? ????
???????????????? ?????????? ????? ???? ???????????? ???? ?? ????? ??? ?????? ???????????? (58). 
??????????????????????????????????????????????????????????????????????????????????????
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being one of them (59,60)?????????? ????????????????????????????????????? ???????????????
???????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????
colorectal cancer and chronic hepatitis with hepatocellular carcinoma (58,61).
????????????????????????????????????????????????????????????????????????????????????????
???????????? ????????????? ????????????????????????? ???????????? ??? ?????????? ??? ??
host’s response to pathogens, chemical irritation or tissue injury. The early stage or acute 
??????????????????????????????????????????????????????????????????????????????????????
????????????? ???????????????????? ????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????? ???????????
??????????????????????????????????????????????? (62)?? ?????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????? ?????????????????????????????????????????????????
?????????????????????????????????????????????(62,63)?? ??????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????? ???????????????????????????????????? ???????????
?????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????? ?????????
lesions (61,63).
?????????????????????????????????????????????????? ??????????????????????????????????
???????? ???????????? ??????????? ???? ????? ??? ????????? ???? ????? ??? ?????????? ??????????
example of an extrinsic pathway is the increased risk of gastric cancer caused by H.Pylori 
infection. In the intrinsic pathway genetic changes cause neoplasias. These mutations 
????????????????????????????????? ???????? ???? ?????????????? ????????????????????? ????
????????????????? ??? ?????? ????????????? ???????????? ??? ???????? ??? ??????? ???? ??????
microenvironments ????????? ????????? ?????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
factor 1a (HIF1alpha) pathways in tumor cells. Tumor cells produce chemokines and 
?????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????? ????
???????????? ?????????????????????????????.
???????????????????????????????????????? ???????????????????? ???????????????????????
macrophages (TAM) and neutrophils (TAN). In addition, dendrite cells, natural 
??????? ?????? ????????? ???????????????????????? ???? ????????????????? ?????????? ??? ??????
microenvironments (66,67)???????????????????????????????? ?? ?????? ???????????????????????
????????????? ????????????????????????????????????????????????????????????????????????
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???????????????????????????????????????????????????????????????????????? ?? ???????????
produce type-II protumorgenic cytokines (interleukin 10, Transformative growth factor-
?????????????(68).
????????????????????????????
Fibroblasts are an important part of normal connective tissue and they synthetize ECM-
?????????????????????????????????????????????????????????????????????????????????????????????
factors and proteinases and regulate the surrounding cells, ECM and basement membrane 
????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????(71).
??????? ?????? ??????? ???? ?????????? ??? ?????????????????? ?????????????????? ???????????
(CAFs) in stroma.  These cells are large spindle shaped cells that look like mesenchymal 
???????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????(72,73). CAFs are not only derived from one cell type. 
???????? ?????????????????????????????????????????????????????? ?????????????????????
In addition, it has been suggested that CAFs are transformed from epithelial cells by EMT 
and from endothelial cells by the endothelial-mesenchymal transition (EndMT) (73). CAFs 
?????????????????????????????????????????????????????????????????????????????????????????
(FSP1). FSP1 from CAFs can promote tumor growth. In addition, conditioned CAFs-
media can induce EMT in tumor cells in vitro ????. Worse survival rates have been reported 
for oral cancer patients with higher amounts of CAFs (75-77).
Toll-like receptors
Toll like receptors (TLR) recognize various endogenous and exogenous components and 
are a type of pattern recognition receptors. TLRs are family of transmembarane proteins 
???? ?????????? ???? ?????????????????????????? ???????????????????????????? ???? ???????
immunity system and they are also active in adaptive immunity. TLRs are found in all 
epithelial and endothelial cells, in cells of the immune system, and in adipocytes (78,79). 
TLRs recognize damage associated molecular patterns (DAMPs) and pathogen associated 
molecular patterns (PAMPs). DAMPs are endogenous components e.g. nuclear acids or 
proteins released during necrosis or tissue damage. PAMPs are conserved structured from 
bacteria or viruses (80,81). TLRs have a three-part structure: a leucine-rich repeat in the 
ectodomain, a transmembrane domain, and an IL-1receptor TIR-domain in the cytosol 
(82). Activation of TLR leads to dimerization of two TLRs and the association of myeloid 
differentiation primary response protein 88 (Myd88) with the cytoplasmic side of the 
????? ???? ????? ???????? ???? ??????????? ??? ????????????????????? ????????? ?????????? ??
bridging adaptor Myd88-adaptor-like protein MAL is needed for Myd88 recruitment (83). 
In TLR-3 exclusively Toll/interleukin 1 receptor (TIR)-domain-containing adaptor protein 
inducing interferon-beta adaptor protein (TRIF) is used to activate the Myd88-independent 
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??????????????????????? ????????????? ????????????????????????????????????????????
TRIF-related adaptor molecule (TRAM release) adaptor proteins are available ????. Finally, 
?????????????? ????????????????????????????????????????????????????????????????????????????
????????????????????????????????????(85).
TLRs have double roles in cancers: TLR agonists are capable of activating the innate and 
????????????????????????????????????????????????????????????????????????????????
has been studied for the treatment of various cancers e.g. colorectal-, breast-, and lung 
cancers (86).  However, tumor cells can recruit immune cells to the tumor microenvironment 
and these immune cells produce tumor-promoting cytokines (87). In vitro oral cancer 
????????????????????????? ???????????????????????????????????? (88). The table below gives 
an in depth description of TLRs with their cellular localization, adaptor molecules and 
expression in various cancers (Table 5).
Figure 7. ??????????????????????????????????????????????????????? ???????????????
????????????????????????????????????????????????????????????????????????????????????
??????????????? ????????????????????????????????????????????????? ????????????????
capable of using the Myd-88 pathway and the Myd-88 independent pathway with TRIF 
???????????????????????????????????????????????????????????????????????????????????
Publishing Group (NPG) ????).
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TLR-4
????????????? ??????????????????????????????????????????? ???????????????????????? ?????????
induce or promote cytotoxic T-cell response towards tumor cells. In wound healing TLR-
?????????????????????????????????????????????????????(89,90). Various immunomodulators 
????? ????? ?????????? ???? ?????? ?????? ??????????? ????????????????????? ??????? ????
??? ?????? ???????????? ??? ????? ???????? ????? ????? ???????? ??? ????????? ??????????????
??????????????????????????????????????????? ??? ??????????????????????? ????????? ???
patients (91)?????????????????????????????????????????????????????????????????????????????
and cytokine production of oral cancer cell lines in vitro (92). ?????????????????????????????
been reported  (88).      
TLR-5
TLR-5 is a bacteria-recognizing receptor in the cell membrane. TLR-5 expression has 
been associated with various cancers e.g. gastric and cervical cancers ???????. TLR-5   ligand 
??????????????????????????????????? ??????????????????? ?????????????????????????????????????
expression in vitro (88). TLR-5 is suggested to be an independent predictor of oral tongue 
cancer mortality (95)?????????????????????????????????????????????????????????????????
to be capable of activating antitumor immune response by stimulating natural killer cells 
and CD8+ T-cells (96). It appears that the role of TLR-5 in various cancers is still somewhat 
unclear (87). 
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TISSUE PROTEINASES
Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) are a family of zinc binding endopeptidases.  There 
???????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????? ?????????????????????????????????????????????
proteins. The basic structure of MMPs includes an amino-terminal pre domain, a 
prodomain (or propeptide domain) and a catalytic domain with an active zinc-binding 
site.  A simple hemopexin domain connected to the catalytic site with a hinge is found in 
all the MMPs except in the minimal domain MMPs (7 and 26) and in MMP-23 (Figure 8). 
MMPs are synthetized in an inactive form and their activation requires the cleaving of a 
prodomain. ProMMPs are mainly cleaved by other MMPs (99,100). MMPs are regulated by 
metalloproteinase tissue inhibitors (TIMP) gene expression and by other MMPs (100-102). 
MMPs are capable of degrading most ECM molecules and MMPs can change cell-to-ECM 
junctions and thus increase cell motility. MMPs also affect cell-signaling pathways ?????????. 
Increased levels of MMPs are found in various cancers and their expression correlates 
with reduced survival. Due to their ability to process non-matrix bioactive substrates such 
as cytokines, growth factors and chemokines, MMPs are known to have pro- and anti-
tumorigenic effect on tumors (99,103-105). The table below describes MMPs and their ECM-
substrates (Table 6). 
Figure 8. Basic structures of MMPs: A) An aminoterminal predomain, a prodomain 
and a catalytic domain with an active site zinc atom. B) Basic MMP structure with a 
hemopexin domain linked by a hinge region to the catalytic domain.
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MMP-7
MMP-7 (Matrilysin) is mainly expressed in mucosal tissue and is the smallest member of 
the MMP-family (107). MMP-7 degrades various ECM proteins e.g. gelatins and collagen 
type-IV and laminin (108).  Increased expression of MMP-7 has been reported in infected 
tissue and in various cancers e.g. oral, skin, colon, lung and breast cancers ?????????. In the 
tumor microenvironment, tumor cells are the main source of MMP-7 in contrast to other 
MMPs (115). In an in vitro study, MMP-7 mRNA silenced breast cancer cell lines had 
reduced proliferation. When these silenced cancer cells were injected to an in vivo murine 
??????? ??????????? ???? ????????????? ?????? ??????? ?????? ???? ?????? ????? ??????????
silenced carcinomas (116). In oral cancer MMP-7 expression is localized in the invasive 
front (115-117).
MMP-8
MMP-8 (Collagenase-2) is mainly found in polymorphonuclear (PMN) leukocytes but is 
present also in many other PMN-lineage cells (118,119). MMP-8 is very potential in degrading 
type-I collagen but is also capable of degrading other collagens. MMP-8 expression has 
been reported in breast, oral and colon cancers (120,121). An increased risk of skin cancer 
and delayed wound healing are reported in MMP-8 null mice. In addition, MMP-8/-- mice 
have a greater risk for tongue OSCC.(105,122,123). MMP-8 expression is associated with the 
survival of tongue OSCC patients (123).    
MMP-9
MMP-9 (Gelatinase-B) is normally present in PMN leukocytes and has a role in normal 
?????????????????????????????????????????????????????????????????????????????????
pathological conditions such as bone resorption, chronic wounds and malignancies ?????. 
MMP-9 is induced by growth factors, chemokines and by other secretive factors (125). 
In the literature, MMP-9 is associated with pro- and anti-tumorigenic effects. Increased 
expression of MMP-9 expression is found in colon, breast and skin cancers (99). MMP-9 
promotes tumor invasion and angiogenesis by releasing and activating TGF-? and VEGF 
in vitro (126). In contrast, some studies suggest that MMP-9 down-regulated cancer cells 
cannot metastasize and MMP-9 is capable of reducing cancer cell apoptosis. In addition, 
MMP-9 null mice showed a decrease in distant metastasis (127-129). In oral cancer, higher 
MMP-9 expression is found when compared to normal tissue and MMP-9 expression is 
associated with poorer survival in HNSCC (130,131).
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Table 6. ???????????? ?????????????????????????????????????????????????????????
the permission from NPG and Wolters Kluwer Health, Inc. (99,100,106)).
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HISTOLOGICAL RISK ASSESSMENT MODEL
Histological risk assessment (HRA) models are developed to clarify the prognosis of 
different tumors. In oral cancer, a subset of patients will develop local recurrence in 
spite of clean resection margins. To distinguish these more aggressive cancers from their 
less aggressive counterparts, various researchers have proposed different histological 
multivariable models. HRA models (Brandwein-Gensler et al (2005) and Almangush et 
al. ???????????????????????????????????????????????????????????????????????????????????
based on tumors and tumor microenvironments and the model is associated with prognosis 
in oral cancer. The worst pattern of invasion (WPOI), lymphocytic host response (LHR) 
and perineural invasion were the studied histological variables in the Brandwein-Gensler 
model. (132,133) The WPOI is the area at the invasive front where the worst type of invasion 
????????????????? ??????????????????????????????????????????????????????????????????
BD, which stands for tumor budding and depth of invasion. This model is associated with 
poor prognosis in early-stage oral tongue cancer ?????????.
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AIMS OF THE STUDY
??????????????????????????????????????????????????????????????????????????????
order to clarify their different clinical behavior. The following study questions were 
formulated:
?? Do OSCC and CSCC have different histological invasion patterns? 
?? Are E-cadherin and Snail expression different in OSCC and CSCC and can they 
explain the different behaviors of these tumors?
?? How do Syndecan-1 and -2 expressions differ between OSCC and CSCC?
?? Are MMP 7,-8, and -9 differently expressed in OSCC and CSCC? 
?? ?????????????????????????????????????????????????
o ????????????????????????????????????????????????????????????????????????
of oral and cutaneous cancer cell lines in vitro?
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MATERIALS AND METHODS
PATIENT MATERIAL AND SAMPLE COLLECTION (I-IV)
We enrolled all the early stage (T1/T2NOM0) non-tongue oral and head and neck cutaneous 
squamous cell carcinomas treated between 2001-2010 in Helsinki University Hospital 
??? ???? ??????? ???? ????????? ????? ?????????? ????? ???? ??????? ????? ?????????? ????????????
system) from the Department of Pathology, Helsinki University and Helsinki University 
Hospital. In total 63 patients were enrolled into this study. In publications I and III 36 were 
OSCC and 25 were CSCC patients, in publication II 35 were OSCC and 25 were CSCC 
patients, and in publication IV 36 were OSCC and 27 CSCC patients. The number of 
patients in the publications varied according to available tumor material. All the patients 
??????????????????????????????????????????????? ??????????????????????????????????????
embedded (FFPE) tissue blocks from the archives of the Department of Pathology. An 
??????????????????????????????????????????????????????????????????????????????????????????
7) shows the clinicopathological variables.   
STUDY ETHICS (I-IV)
The Local Ethics Committee of Helsinki University Central Hospital approved this study 
Dnro (198/13/03/02/2009). All the work has been done in accordance with the Declaration 
of Helsinki.
EVALUATION OF INVASION MODEL (I)
The Brandwein-Gensler model was the most suitable invasion model and thus was used 
in this thesis. WPOI was evaluated on normal HE-slides at the invasive front in the areas 
????? ?????????? ????????? ?????????????????????????????? ????? ??????????????????? ???????
??????????????????????????????????????????????????????????????????????????????????????
tumor islands, or in a broad bushing manner (Type 2), tumor invasion in a separate tumor 
island with more than 15 cells per island (Type 3), tumor islands with less than 15 cells 
???? ?????????????????????? ??????????????????? ??????????????????? ??????????????????????
continuous lymphoid tissue surrounding the tumor (Pattern 1), large lymphoid tissue 
patches at the interface (Pattern 2), little or none lymphoid tissue (Pattern 3) (132). We used 
?????????? ????????????? ????? ??????????? ?????? ?????? ?????? ??? ??????????????????????
model (Table 8). 
???????????????????????????????? ??? ???? ?????????? ????? ??????? ?????? ???????????????
CAFs (Type 0), stromal CAFs with epithelioid or spindle morphology (Type 1), Spindle 
CAFs patterns in stroma (Type 2), dense overlapping CAFs throughout the whole stroma 
(Type 3) (136). The evaluation was done by A.A.
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Table 7. Clinicopathological variables of the study population. 
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IMMUNOHISTOCHEMISTRY (I-IV)
Automatic immunohistochemical (IHC) staining for the slides was performed in a 
????????????????????????????? ???? ??????????? ??? ????? ??????????? ????? ???????????
??????? ???????? ????????????????? ?????? ???????????? ???????????? ????????????? ???
min incubation on DAKO peroxidase-blocking solution (Dako, Glostrup, Denmark). 
The primary antibody incubation lasted for 1h. The primary antibody incubation was 
followed by a30 min incubation with the Dako Real Envision/HRP detection system 
(Dako, Glostrup, Denmark). For visualization Dako REAL DAB+ Chromogen ((Dako, 
Glostrup, Denmark) was used. The slides were washed with phosphate buffered saline 
???????????????????????????????????????????????????????????????????????????????????
as a positive control. Samples without primary antibody were used as a negative control. 
Manual IHC staining was performed according to the following protocol: The slides 
??????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????? ???????????????????????????? ?????????????? ? ????????
hydrogen peroxidase solution was added for 20 min at room temperature (RT) to block 
endogenous peroxidase activity. The Vectastain Elite ABC kit (Universal) (Vector 
Laboratories, Burlingame, CA, USA) was used for IHC.  Thirty-minute incubation at 
??? ????? ???? ??????? ?????? ??????? ???? ????? ??? ?????? ??????????? ????????? ???? ???????
??????????????????????????????????????????????????????????????????????????????????????
??????????????????? ??????????????? ????????????????????????????????????? ??????????????
??????? ??????????? ???? ?????????? ????????????? ?????????? ??????????????? ????????????
9-ethylcarbazole (AEC) and counterstained with Hematoxylin (Merck KGaA, Darmstadt, 
Germany). Between each step, the slides were washed with PBS. The Manual IHC method 
????????????????????????????????????????????????????? ?????????????????????? ??????????????
???????? ????????????????????????????????????????????????????????????????????????
Table 8.??????????????????? ??????????????????????????????????????????????????????
permission from Wolters Kluwer Health, Inc. (132)).
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EVALUATION OF IMMUNOHISTOCHEMISTRY (I-IV)
The immunohistochemical staining results were evaluated in a semi-quantitative manner. 
Scores varied from 0 (no staining), 1 (mild staining, 30% or less), 2 (moderate staining, 
???????????????????????????????????????????????? ?????? ??? ?????????????????????????
?????????????????? ??????(139).  The slides were evaluated separately by J.H and A.A and 
if any disagreement emerged the slides were re-evaluated until consensus was achieved.
Table 9. A list of used antibodies * (137,138), monoclonal antibody (mAb), polyclonal anti-
body (pAb)
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STATISTICAL ANALYSIS (I-IV)
To test for differences between OSCC and CSCC in their clinicopathological variables 
or in their IHC staining results, non-parametric tests were used. When possible, cross 
tabulation with the Fisher exact test was used. Otherwise the Mann-Whitney U-test was 
used. Kendall’s Tau was used to test for correlation. In the cell culture studies the univariate 
t-test and Manova were used.  All the tests were two-tailed and a p-value of 0.05 or less 
??????????????????????????????????????????????? ??????????? ?????????????????????????????????
were performed with the Kaplan Meier test and log-rank test was performed to test for 
differences between OSCC and CSCC. The follow-up times were calculated from the time 
of diagnoses (PAD) until death or the end of the follow-up period. The median follow-up 
??????? ???????? ????????????????? ??????? ???????? ??????????? ????????????? ??????
(min = 11.0 months and max = 60 months) for CSCC. 
CELLS AND CELL CULTURE (IV)
Oral tongue carcinoma cell lines HSC-3 (JCRB0623) and SAS (JCRB0620) were 
??????????? ??? ???? ??????????? ???????? ?????? ??????? ???????????? ?????????????
Carlsbad, CA, USA) with 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA), 100 
??????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????? ?????????????????????????????????
positive gingival keratinocyte (IHGK) was cultured in keratinocyte serum free medium 
(keratinocyte-SFM) (Gibco, Carlsbad, CA, USA) and treated with 100 U/ml penicillin, 
????????????????????????????????????????????????????????2 (all from Sigma-Aldrich, 
????????????????????????????????????????????????????????????????????????????Carlsbad, 
CA, USA)   ??????? ????????? ???????????????????? ??????????????????????? ??? ?????????????
in DMEM (high glucose) and treated with 10% fetal calf serum (Invitrogen, Carlsbad, 
CA, USA), 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mmol/l sodium pyruvate, 50 
??????????????????????????????????????????????????????????????????? ????? ???????????
Aldrich, Ayrshire, UK)  ??????????????????????????????????????????????????????????????????
CO2????????????
CELL PROLIFERATION AND MIGRATION (IV)
Twenty-four or forty-eight-hour proliferation assays were performed for HSC-3, SAS, 
?????? ????????? ????? ??????????? ??????????? ????? ????????? ??? ???????? ??????? ???? ???? ????
afterwards washed with PBS. Serum-free Opti-Mem (Invitrogen Carlsbad, CA USA) 
??????????????????????????????????? ???????????? ????????????? ???????????????????????
USA) was added. Six parallel assays were performed. After the incubation period, BrdU 
labelling solution was added and the absorbance values were measured according to 
the manufacturer’s instructions (Cell Proliferation ELISA BrdU, Rocher, Mannheim, 
Germany). 
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?????????? ???????????? ?????????? ???? ??????????? ????? ?????? ????? ??????? ????? ???????
In HSC-3 80 000 cells per well were used whereas for other cell lines 100 000 cells per 
?????????????????????????? ????????????????????????????? ???????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????? cell culture media (1% 
FBS media), apart for the IHGK cell lines where Opti-MEM (Gibco, Carlsbad, CA, USA) 
was used. The images were captured with a Leica microscope at the beginning and at 
regular intervals during the migration assay. All the analyses were performed with ImageJ 
software ?????.
ORGANOTYPIC MYOMA INVASION MODEL (IV)
?????????????????? ?????????????????????????????????????????????? ????? ????????????
lines. The method is described in more detail by Nurmenniemi et al (2009) ?????. Myoma 
discs prepared from the uterine leiomyoma were placed into a transwell and 700 000 cells 
??????????????????????????????????? ????????????????????????????????????????????????
well plates. The cell culture media was changed every three to four days. The myomas 
?????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????? ?????
????????????????????????????????????????????????????????????????????????????????
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RESULTS
HISTOLOGICAL RISK ASSESSMENT MODEL (I)
The WPOI distributions in OSCC and CSCC were different. OSCC had poorer WPOI 
?????????????????????????? ?????????????????????????????????????? ??????????????????
?????????????????????????????????????????????? ???????????????????????????????????
distribution of CAFs around the tumor were similar for both OSCC and CSCC (Figure 9). 
??? ????????????????????????????????????????????????????????????????????????????????????
and 8.3% (3 patients) had poor overall survival probability according to the HRS. In 
????? ?????? ???? ?????????? ???? ?????? ?????? ???? ?????????? ????????????? ???? ?????? ???
patients) poor overall survival probability according to the HRS. No statistical differences 
were found between OSCC and CSCC by the HRS. The HRS was not associated with 
??????????????????????????????????????????????????????
In OSCC, invasion depth correlated with CAFs and with WPOI (r = 0.522 p = 0.05, r = 0.3 
p = 0.025 respectively). In CSCC, CAFs were associated with invasion depth (r = 0.522, 
?????????????? ??????????????????????????????????????????????????????????????????
Figure 9. Worst pattern of invasion (WPOI): invasion in a broad pushing bor-
der (Type 1) (a), large tumor islands (Type 2) (b), tumor invasion with a sepa-
rate tumor island having more than 15 cells per island (Type 3) (c), tumor islands 
????? ????? ????? ??? ?????? ???? ??????? ??? ??????? ????? ????????? ?????? ??? ???? ????????????
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SURVIVAL ANALYSIS (I, III)
???????????? ????????????????????????????????? ??? ????????? ????? ??????????????????????
Overall survival for OSCC was 69.7% (2-years) and 55.1% (5-years), and for CSCC 
?????????????????????????????????????????????????????????????????????????????????
(2-years), 62.1% (5-years) and 91% (2-years), 79.7% (5-years) respectively. OSCC had a 
?????????????????????????????????????????????????????????????????????? ????????????????????
???????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
OSCC and CSCC in overall survival (Figure 11).
Figure 10. The density of CAFs: tumor stroma with no CAFs (Type 0) (a), stromal CAFs 
with epithelioid or spindle morphology (Type 1) (b), spindle CAFs patterns in the stroma 
(Type 2) (c), dense overlapping CAFs throughout the whole stroma (Type 3) (d). (10x mag.). 
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Figure 11????????????????????????????????????????????????????????
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E-CADHERIN AND SNAIL (I)
In normal oral and cutaneous tissue E-cadherin expression was cell membranous. 
E-cadherin was expressed on carcinoma cell membranes in both OSCC and CSCC. 
Some cytoplasmic E-cadherin expression was also found in carcinoma cells. E-cadherin 
expression was lost in the invasive fronts of both tumor types’ cell membranes. No 
differences were found between OSCC and CSCC in E-cadherin expression.
Similar snail expressions were found in normal oral and cutaneous tissue. Snail was 
detected mainly in the cell nuclei of OSCC and CSCC tumors. In addition, diffuse 
cytoplasmic Snail expression was found in OSCC and CSC. 
SYNDECANS (II)
Syndecan-1 
Cell membranous syndecan-1 expression was found in normal oral and cutaneous tissue. 
Cytoplasmic and cell membranous syndecan-1 expression was found in the carcinoma 
cells in both OSCC and CSCC. Syndecan-1 expression was lower in the invasive front of 
the OSCC (p = 0.018, Fisher Exact) and CSCC (p < 0.001, Fisher Exact) when compared 
to normal oral and cutaneous tissue.  Syndecan-1 expression in the invasive front of the 
OSCC and CSCC was negatively associated with invasion depth (r = -0.339 p = 0.025, 
????????????????????????????????????????????????????????
?????????????????? ??????????????????????????? ???????????????????????????????? ????
???????????? ?????? ???? ????????? ??????? ????? ????? ?? ???? ???? ??????? ??? ???????????
??????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
cells when compared to patients with none to moderate stromal syndecan-1 expression in 
??????????????????????????????????????????
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Syndecan-2
In normal oral tissue no syndecan-2 expression was found and in normal cutaneous tissue 
mild syndecan-2 expression was found. Syndecan-2 expression was mainly cytoplasmic 
and similar throughout the tumor epithelium of OSCC and CSCC. No differences were 
found in syndecan-2 expression between OSCC and CSCC. 
????????????????????????????????????????? ???????????????? ???????? ????????????????
cells. In non-malignant stroma surrounding a tumor, syndecan-2 expression was higher in 
???????????????????????????????????????????????????????? ????????????????????????????
???????? ??????????????????????????????????????????????????? ?????????????????? ????????
???????????????????????????????????????????????????
MMPs (III)
In normal oral epithelium low levels of MMP-7 expression was detected and in normal 
cutaneous tissue no expression was found. MMP-7 was expressed in OSCC and CSCC 
tumor cells in separate small cell islands and in single cell invasion manner. The main 
MMP-7 expression was located in the invasive fronts of tumors (Figure 12a and b). MMP-
7 expression in the invasive fronts of tumors was higher in OSCC than in CSCC (p = 
0.017, Mann-Whitney).  
Very mild MMP-8 expression was present in normal oral and cutaneous tissue but no 
MMP-8 expression was found in OSCC and CSCC cells. Interestingly, peritumoral 
???????????????????????????????????????????????????????????????????????????????????
found between OSCC and CSCC in their MMP-8 expression.  
In normal oral and cutaneous epithelium only a mild MMP-9 immunopositivity was 
found.  Carcinoma cells of OSCC and CSCC were positive for MMP-9 throughout the 
??????? ?????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????
12e and f). 
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Figure 12. Immunohistochemical staining for MMP-7, MMP-8 and MMP-9. Strong MMP-
7 expression in the OSCC invasive front (a) and moderate in an CSCC invasive front (b). Neg-
ative MMP-8 expression in the OSCC (c) and CSCC (d). tumor epithelium MMP-8 positive 
??????????? ?????????????????????? ????? ???????? ????? ???????????? ???? ??? ??? ????
????????????????????????? ????????????????????????????????????????????????????? ?????-
?????????????????????? ??????????????????????????????????????????? ??????????????? ?????
50
TOLL-LIKE RECEPTORS (IV)
?????? ???? ??????????? ?????????? ??? ???? ??????? ??? ??????? ????? ??????? ???? ??????????
??????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????? ??????????????????????????????????
???????? ?????????????? ?????????????????? ???????? ???????? ????????????????? ???????
???????????????????????????????????????????????????????????????????????????????????
TLR-5 was expressed only in the basal cell layer of normal oral and cutaneous epithelium. 
In OSCC and CSCC TLR-5 expression was found throughout the whole carcinoma tissue. 
??? ?????????????? ???? ???????? ????????????????????????????????? ???????????????????? ???
OSCC than in CSCC (p = 0.037, Mann-Whitney U test). In OSCC, a negative association 
was found between TLR-5 expression in the invasive front and the pathological 
differentiation grade (r = -0.360, p = 0.015) Otherwise, no correlations were found for the 
clinicopathological features of either OSCC or CSCC.
Proliferation assay
?????????? ????????????????????????????? ???????????????????? ???????? ???? ????? ????????????
????????? ???????? ??? ???? ???????????? ? ?????? ?? ???? ??????????? ????????? ?????????? ????
?????????????????????????????????????????? ????????? ????? ????????????????????? ?????????????
A5 (p < 0.0001, unpaired t-test) cell lines. Flagellin failed to increase the proliferation of 
???????????????????????????????????????????????????????
  
Migration assay
??????????? ????????? ???????????????? ??????????????????????????????????????????????????
???????????????????????????????????????????????????????????? ?????????????????????????
?????????????????????????????? ?????????????? ???????????????????????????????????????????
migration was not seen (Figure 13a, and b).  
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Figure 13a.? ???????????????????????????????????????????? ?????????????????????????????
????????????????????? ???????????? ???????
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Myoma invasion assay
In the organotypic myoma invasion assay the different invasion capabilities of oral and 
cutaneous cancer cell lines were studied. The highly aggressive HSC-3 invaded in string- 
??????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
A5 formed mainly an epithelial layer on the top of the myoma and no invasion was seen 
????? ????????????????????????? ??? ???????????????????? ????????? ??????????????? ??
??????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????? ??????????????????????????????????????????????? ???????????
?????????????????????????????????????????????????????????????????????? ??????????????????????
HSCC-3 cells in the myoma model.
Figure 13b. Wound healing assay of HSC-3 cell lines at three time points.
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Figure 14. HE-staining of traditional myoma invasion assays for HSC-3 (a), SAS (b), 
?????????? ?????????
Figure 15?????????????? ????????????????????????????????????????????? ?????????????????
???????? ?????????????????????????????????????????????????????????????????????????
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DISCUSSION
??????????????????????????????????????????????????????????????????????????????????
differences between OSCC and CSCC. The study was conducted by examining different 
epithelial and stromal factors in tumor and tumor microenvironments. Survival analysis 
was performed. In addition, the types of invasion were studied. 
Our patient cohort consisted 63 patients with 36 early stage OSCCs and 27 early stage 
??????? ?????????????????????????????????????????????????????????????????????????????
????? ??? ?????? ????????? ???? ????????? ???????????????? ????????? ????? ??? ????? ????
??????????????????????????????????????????????????????????????????????????????????????
much older than in the OSCC cohort (mean age 66 years). The studied HRA model HRS 
was not associated with survival of OSCC and CSCC. In addition, the study population 
was small, thus one should beware of over-interpreting the survival data in this study.  
Although various HRA models have been introduced in multiple studies. A HRA model, 
?????????????????????????????????????????????????????????????????????????????????. In order 
to obtain a better understanding of the different HRA models one have to compare 
these studies, such as those by Brandwein-Gensler, Almanguishi, Martinez-Gimeno and 
Odell who have introduced HRA models and used them to investigate OSCC patients. 
The Brandwein-Gensler and Martinez-Gimeno studies patient cohorts involved tongue 
and non-tongue OSCC patients in all the T-stages. The studies by Odell and Almangush 
involved early-stage tongue OSCC patients. All the papers evaluated, at least, the following 
histological variables: pattern of invasion and lymphocytic host response ?????????????????. We 
?????????????? ????????????????????????? ??? ?????? ??????????????????????????????
between OSCC and CSCC. In our study we found that OSCC has a poorer overall WPOI 
score than CSCC. However, HRS revealed that our OSCC and CSCC patients had similar 
overall survival probabilities.   
According to previous studies the amounts of LHR correlate negatively with the survival 
of patients with OSCC (132,133). In our research only a minority of cases had little or no LHR 
and the majority of OSCC and CSCC tumors had dense LHR surrounding the tumors. 
This might be due to the early stage cancers in this study.  LHR might regulate the host 
????????????????????????????????????????????????????????????????????????????????????????
????? ???????????? ??? ????????????????? ???? ??????? ?? ???????? ????????????? ???? ????????
????????????????????????????????????????????????????????????????????????????????.
????????? ??? ???????????????????????? ?????????? ????????????????? ??????????? ????
whole tumor stroma. In addition, the CAFs in our study were associated with the invasion 
depth of both the OSCC and CSCC. It has been reported that OSCC patients who have 
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tumors with higher amounts of CAFs in their stroma have lower overall survival rates (136). 
CAFs can be seen more as a phenotype than as single cells inducing tumor progression. 
This change in phenotype might be related to increased communication between tumors 
and their microenvironments ?????.
?????????? ???????????? ??? ???? ?????????????????????? ??????????? ???? ????? ?????? ??? ?????
reported in the invasive front of tumors ????????. According to the literature Snail down-
regulates E-cadherin (151). In OSCC, the loss of E-cadherin has been associated with poorer 
survival (152). In our OSCC and CSCC patients the loss of E-cadherin in the invasive fronts 
????????????????????????????? ????????????????????????????????????????? ???????????
no differences were found between OSCC and CSCC for E-cadherin or Snail expression. 
In the literature the loss of epithelial cell membranous syndecan-1 expression has been 
associated with diminishing adhesion and loosening of the attachment to the ECM. This 
??????????????????????????????? ?????????????????????????????????????(153). In OSCC, the loss 
of syndecan-1 has been associated with poor prognosis and lymph node status ????????????. 
A decrease in syndecan-1 expression may similarly enable the cells to invade deeper. 
In our results syndecan-1 expression in tumors correlated negatively to invasion depth 
????????????????????????????????
In various cancers increased stromal syndecan-1 expression has been hypothesized to be 
part of tumor invasion and metastasis and in some studies this has been associated with 
poor prognosis (153,155-159). In our study, deeply invasive OSCC tumors had higher amounts 
?????????????????????????????????????????????????????????????????????????????????? ?????
be due to soluble syndecan-1 molecules, which might be inducing tumor progression. 
Stromal syndecan-1 expression was less common in deeply invasive CSCC samples than 
in their OSCC counterparts. 
Syndecan-2 has been rarely studied in oral or in cutaneous cancers. In the literature, 
increased syndecan-2 expression has been reported to have tumorigenic properties in vitro 
(160). However, curiously, in pancreatic carcinomas, epithelial syndecan-2 expression was 
positively associated with their prognoses and stromal syndecan-2 expression had no effect 
on their prognoses (161). In our study OSCC and CSCC had similar syndecan-2 expression 
in tumor and in tumor stroma but syndecan-2 expression was distinctly different in the 
non-malignant stroma of OSCC and CSCC.  Syndecan-2 expression of non-malignant 
stroma was higher in CSCC than in OSCC. 
In some prostate carcinoma studies the properties of non-malignant stroma such as 
??????????????????????????????????????????????????????????????????????????????????????
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?????????????????????????????(162). The reason behind the abundant syndecan-2 expression 
in the non-malignant stromal tissue of CSCC could be the role of syndecan-2 in melanin 
synthesis (163). However, more research is needed to clarify the role of non-malignant 
stroma and the role of syndecan-2 in these tumors. 
 
MMPs have been thoroughly studied in various cancers. Lately in addition to the 
proteolytic functions of MMPs, their immunomodulatory functions have been reported 
?????. While MMPs have been associated with tumor invasion and progression also some 
anti-tumorigenic potential has been reported for MMPs (99,123). During tumorgenesis the 
up-regulation of MMP-7 has been reported and the expression is mainly situated in the 
invasive front of the tumor (116,165). Similarly, in our study MMP-7 expression was mainly 
in the invasive front of tumors and this was higher in OSCC than in CSCC. MMP-7 
expression has been associated with invasion and aggressive types of cances (115,117). Our 
????????????????????????????????????????????????????????????
MMP-8 expression has been detected in various epithelial cancers e.g. oral, colon, and 
breast cancers. MMP-8 expression has been associated with anti-tumorgenic effect both 
in vitro and in vivo (120-123). Increased levels of MMP-9 have been reported in oral, skin, 
breast, and colon cancers (130,166-168). In our early stage OSCC and CSCC tumors, MMP-
8 was absent and MMP-9 was mildly expressed in the tumor epithelium. MMP-8 and 
??????????????????????????????????????????????????????????????????????????????????
are different from previous studies. We were not able to identify MMP-8 expression in 
????????????????????????????????????????????????????????????????????????????????????????
main source of MMP-8 and -9 in the tumor microenvironment.
???????????????????????????????????????????????????????????????????????????????????????
cells, lymphocytes and dendritic cells are part of the tumor microenvironment  (66,169). Tumor 
?????????????????????????????????????????????????????????????????????????????????????
MMPs are capable of controlling and cleaving chemokines (170,171). In the literature, as well 
?????????????????????????????????????????????????????????????????? ??????????????? ?????
and MMP-9 in the tumor microenvironment (172,173).  MMP-8-/- mice have been reported to 
have increased risk for cutaneous cancers and MMP-9-/- mice have diminished neutrophil 
?????????????????????????. In vitro, cancer cells (head and neck) have been reported to be able to 
induce the release of MMP-9 from PMN-cells and in addition MMP-9 can sustain chronic 
????????????(66,175-177)?? ?????????????????????????????????????????????????????????????
role in the carcinogenesis of SCC (178).
MMPs are capable of activating each other and especially MMP-7 can activate 
proMMP-9 (179,180). One could speculate that MMP-7 from the tumor epithelium could 
?????????????????????????????????????????????????????????????????????????????????
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In addition, MMPs are capable of shedding syndecan-1 and could in some conditions 
induce tumor invasion (155,181).
??????????????????????????????????????????????????????????????????????????????????????
been found in various tumors e.g. head and neck cancers and colon cancers and it has been 
associated with tumor progression (89,182). In in vitro?????????? ?????????????????????????
shown potential for inducing proliferation and cytokine production (88,182). However, TLR-
???????????????????????????????? ?????????????????????????????????? in vivo (183). TLR-
?????????????????????????????????????????????????????????????????? in vitro. In previous 
?????????????????????????????????????????????????????????????????????????????????????????
(88). In addition, TLR-5 expression has been associated with increased mortality in tongue 
OSCC (95). In our study TLR-5 expression was situated in the basal cell layer in normal 
oral and cutaneous tissue. In OSCC and CSCC, TLR-5 was expressed throughout the 
tumor epithelium and TLR-5 expression in the center of tumor was higher in OSCC than 
in CSCC. 
??????????? ?? ???????? ?????? ???????????????????????????? ????????? ??????????????? ???? ????
contested ?????????? ????????????????????????????????????????????????????????????????? ?????????
of oral and cutaneous cancer cell lines. Flagellin was able to increase proliferation, 
invasion, and migration of less aggressive oral cancer cell lines and all the studied 
cutaneous cancer cell lines. In addition, migration of non-malignant HPV transfected 
????????????????????????????????????????????????????????????? ???????????????????????
???????????? ??? ???????????? ???? ??????? ??? ????????? ??? ??????????? ???? ?????????? ?????
????????????????????????????? ?????????????????????????????????????? ????????????????????????
cell line but failed on the highly aggressive HSC-3 cell line. One explanation could be 
that in OSCC more abundant TLR-5 expression is found when compared to CSCC and in 
addition to this the TLR-5 pathway is already endogenously activated in aggressive oral 
cancers. Our in vitro???????????????? ??????????? ??????????????????? ??????????????????
might lead to more aggressive and invasive behavior of less aggressive cancer cell lines. 
An overview of the studied molecular markers in OSCC and CSCC is given in the table 
below (Table 10).
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STUDY LIMITATIONS AND FUTURE DIRECTIONS
The patient material of the study was small and collected retrospectively, thus a possibility 
of selection bias was present. The study was single centered and all the clinical data were 
not available to the researchers.  
We were not able to study the activation of the metalloproteinases in vitro, which makes 
??? ????????? ?????????????? ???? ???????? ???????? ??? ????????????????????????????? ?????
problem is evident in almost all of our papers. As immunohistochemistry was almost the 
only method used, validation of the results with other methods was not undertaken. We 
?????????????????????????????????????????????????????????????????????????????????????????
induction of cytokine production.
?????????????????????????????????????????????????????????????????????????????????????
be a multicenter clinicopathological study on HRA models and survival. The second 
path would be collecting individual tumors and studying mutations and the invasion 
capabilities of each tumor in vitro. 
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CONCLUSIONS
Taken together OSCC and CSCC are epithelial cancers which progress and invade in 
similar steps. As described previously, OSCC has a poorer prognosis than CSCC, thus 
single or more likely multiple differences should be found between these tumors. These 
differences, if present, are situated in the tumor cells, in the tumor stromal cells, in the 
communication between tumor cells and stromal cells or in the communication within 
tumor cells or stromal cells. In our study, OSCCs and CSCCs expressed the following 
histological, epithelial and stromal markers differently:
OSCC had poorer WPOI than CSCC, but stromal LHR and CAFs were similarly 
expressed in OSCC and CSCC but did not predict OSCC or CSCC behavior.
E-cadherin and Snail were similarly expressed in OSCC and CSCC tumors. In both 
OSCC and CSCC, E-cadherin expression in the tumor epithelium decreased in the 
invasive fronts. E-cadherin and Snail expression could not explain the different 
behaviors of these tumors in our study.
Syndecan-1 expression decreased similarly in the invasive fronts of OSCC and 
CSCC possibly the result. Syndecan-1 expression in stromal tissue of tumors with 
??????????????????????????????????????????????????????????? ???????????????
soluble syndecan-1 expression might induce this invasion. 
MMP-7 was expressed mainly in the invasive fronts of OSCC and CSCC and the 
expression was stronger in OSCC. MMP-8 and -9 were absent from the tumor 
??????????? ???? ????? ??????? ??? ???????????? ???????????? ?????? ???? ??? ?????
peritumoral MMP-9 was more abundant than it was in CSCC.
TLR-5 was more strongly expressed in OSCC than in CSCC. In in vitro studies, 
?????????????????????? ????????????????????????????????????? ??????????????????????
of less aggressive oral and cutaneous cell lines. Flagellin had no effect on the most 
aggressive oral cancer cell line.
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Abstract 
Objectives:   Oral squamous cell carcinoma (OSCC) has poorer prognosis than cutaneous squamous 
cell carcinoma (CSCC).Both are epithelial neoplasias, but the reasons for the difference in behavior are 
poorly known.  Worst Pattern of invasion (WPOI), lymphatic host response (LHR) and density of 
cancer associated fibroblasts (CAFs) as well as epithelial-mesenchymal transition (EMT) markers E-
cadherin and Snail were studied to create a histological risk assessment model easy to use. 
 
Materials and Methods: Thirty-six OSCC and 25 CSCC with early-stage (T1-T2N0M0) were 
enrolled into this study. Immunohistochemical staining was performed for E-cadherin and Snail.  CAFs 
were examined with alpha smooth muscle actin (?-SMA). WPOI and LHR were addressed.  
 
Results: The OSCC had higher WPOI value than CSCC. LHR and CAFs were similarly expressed in 
OSCC and CSCC. Both in OSCC and CSCC, invasion depth correlated significantly with CAFs. No 
differences were found in E-cadherin expression in tumor epithelium between these tumors. 
 
Conclusions:  Higher WPOI value was reported in OSCC when compared to CSCC.  No difference 
was detected between OSCC and CSCC in LHR or distribution of CAFs. One could suggest that the 
WPOI describes the invasion potential of OSCC and could partly explain the different clinical behavior 
of OSCC and CSCC.?? ?
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